缺血性脑卒中神经保护药物的临床研究进展  

Clinical research progress of neuroprotective drugs for ischemic stroke

作　　者：吴健隆 张潇 江文 WU Jianlong;ZHANG Xiao;JIANG Wen(Xijing Hospital,Air Force Medical University,Xi’an 710032,China)

机构地区：[1]空军军医大学西京医院,陕西西安710032

出　　处：《中国实用神经疾病杂志》2023年第10期1311-1316,共6页Chinese Journal of Practical Nervous Diseases

基　　金：国家自然科学基金(编号:81974204)。

摘　　要：脑卒中是中国致死率最高的疾病,其中缺血性脑卒中占71%。尽管溶栓和取栓治疗领域的突破使缺血性脑卒中的治疗取得巨大进展,但无法接受血管再通治疗的患者仍然众多,实现缺血性脑卒中的神经保护仍面临挑战。在临床前研究中,许多药物表现出神经保护的治疗前景,但在临床试验中未能证明其有效性,目前尚无对缺血性脑卒中有明确疗效的药物。本文阐述了缺血性脑卒中的病理生理机制,总结了具有治疗前景的神经保护药物和目前正在进行的临床研究供研究者参考。Stroke is the leading cause of mortality in China,with ischemic stroke accounting for 71%of all cases.Despite significant progress in the use of thrombolysis and endovascular therapy to treat ischemic stroke,many patients are unable to receive these treatments due to various factors.As a result,achieving effec⁃tive neuroprotection in ischemic stroke remains a major challenge.While numerous drugs have demonstrated promise for neuroprotection in preclinical studies,their efficacy in clinical trials remains unproven.To date,there are no drugs with established efficacy for treating ischemic stroke.This article provides an overview of the pathophysiological mechanisms underlying ischemic stroke,as well as a summary of promising neuroprotective drugs and ongoing clinical trials for reference.

关 键 词：缺血性脑卒中 神经保护 药物治疗 病理生理机制 

分 类 号：R743.33[医药卫生—神经病学与精神病学]